# Bradley J. Monk

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/bradley-j-monk/

## Facts

| Field | Value |
| --- | --- |
| Citations | 45,892 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 94 |
| i10-index | 427 |
| Last Known Institution | Florida Cancer Specialists & Research Institute |
| OpenAlex ID | https://openalex.org/A5014611244 |
| ORCID iD | 0000-0001-6985-0159 |
| Works | 1,000 |

## Researcher papers

Showing 12 of 24.

- [Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer](https://scholariq.org/papers/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer/)
- [Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/incorporation-of-bevacizumab-in-the-primary-treatment-of-ovarian-cancer/)
- [Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix](https://scholariq.org/papers/concurrent-chemotherapy-and-pelvic-radiation-therapy-compared-with-pelvic/)
- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Improved Survival with Bevacizumab in Advanced Cervical Cancer](https://scholariq.org/papers/improved-survival-with-bevacizumab-in-advanced-cervical-cancer/)
- [Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer](https://scholariq.org/papers/pembrolizumab-for-persistent-recurrent-or-metastatic-cervical-cancer/)
- [Carcinogenic human papillomavirus infection](https://scholariq.org/papers/carcinogenic-human-papillomavirus-infection/)
- [Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-ii-trial-of-bevacizumab-in-persistent-or-recurrent-epithelial-ovarian/)
- [Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer](https://scholariq.org/papers/dostarlimab-for-primary-advanced-or-recurrent-endometrial-cancer/)
- [Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-iii-trial-of-four-cisplatin-containing-doublet-combinations-in-stage-ivb/)
- [Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)](https://scholariq.org/papers/bevacizumab-for-advanced-cervical-cancer-final-overall-survival-and-adverse/)
- [Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer](https://scholariq.org/papers/analysis-of-gene-expression-profiles-in-normal-and-neoplastic-ovarian-tissue/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Cervical Cancer and HPV Research](https://scholariq.org/topics/cervical-cancer-and-hpv-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Florida Cancer Specialists & Research Institute](https://scholariq.org/institutions/florida-cancer-specialists-and-research-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.